英赛德 INSM

Mr. William H. Lewis, Chair of the Board since November 2018. Director since September 2012. President and CEO since September 2012. Consultant to Board from June-September 2012. Current Public Board Service: Chair of the Board of Directors, NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS). Education: Oberlin College - B.A.; Case Western Reserve University - M.B.A.; Case Western Reserve University - J.D. Career Highlights: Insmed Incorporated (Nasdaq: INSM) (2012 - present), Chair and CEO (2018 - present), President and CEO (2012 - 2018); Aegerion Pharmaceuticals, Inc. (Formerly, Nasdaq: AEGR) (2005 - 2011), Co-founder, President, Chief Financial Officer; Wells Fargo & Co. (2002 - 2004), Robertson Stephens Capital (2000 - 2002); JP Morgan Chase & Co. (1995 - 2000); Foreign Service for the US Government (1989 - 1992).

Mr. Adsett joined Insmed as Chief Commercial Officer in September 2016 and was promoted to Chief Operating Officer in November 2019. Mr. Adsett has more than 25 years of experience in the global biotechnology and pharmaceutical industry. From January 2015 to September 2016, Mr. Adsett was Senior Vice President, Head of Gastrointestinal and Internal Medicine Business Unit at Shire Plc (Shire), a global specialty biopharmaceutical company. From August 2008 to January 2015, Mr. Adsett was Senior Vice President, Gastrointestinal Business Unit Leader at Shire. From October 2005 to August 2008, Mr. Adsett was General Manager, Oral IBD Products of the Gastroenterology Business Unit of Shire. From November 1994 to October 2005, Mr. Adsett held various marketing and commercial roles at AstraZeneca plc, a multinational pharmaceutical and biopharmaceutical company. Mr. Adsett was a senior analyst at Accenture PLC, a global professional services company, from September 1991 to November 1994. Mr. Adsett served on the board of Landos Biopharma, Inc. (Nasdaq: LABP) until its acquisition by AbbVie in 2024. Mr. Adsett holds a Master of Business Administration from The Wharton School at the University of Pennsylvania and a Bachelor of Arts in English and Economics from Bucknell University.

Ms. Bonstein joined Insmed as Chief Financial Officer in January 2020 and is responsible for the Company's key financial functions, including accounting, financial planning and analysis, procurement, and investor relations. Ms. Bonstein brings more than 20 years of operational and financial leadership in the life sciences industry. Prior to joining the Company, Ms. Bonstein was Chief Financial Officer and Chief Operating Officer of OncoSec Medical Incorporated, positions she held since May 2018. From February 2014 to April 2018, Ms. Bonstein served as the Chief Financial Officer, Secretary, Treasurer and Executive Vice President at Advaxis, Inc. Prior to Advaxis, Ms. Bonstein was a Six Sigma Champion & Black Belt at Eli Lilly and Company (Lilly) from January 2012 to February 2014. From August 2004 to December 2011, Ms. Bonstein served in various finance roles at ImClone Systems (acquired by Lilly in 2008), including Director of Development Finance. From 2001 to 2004, Ms. Bonstein served in various roles at Johnson & Johnson. Ms. Bonstein has served on the board of directors of scPharmaceuticals Inc. (Nasdaq: SCPH) since July 2020 and Xilio Therapeutics, Inc. (Nasdaq: XLO) since August 2021. Ms. Bonstein holds a Master of Business Administration from Rider University and a Bachelor of Science in Finance from The College of New Jersey. On October 5, 2026, Insmed Incorporated announced that Sara Bonstein, the Company's Chief Financial Officer, would be separating from the Company, effective October 30, 2026.

Mr. Smith joined Insmed as Corporate Counsel in April 2014 and was promoted several times, including to the positions of Vice President, Corporate Counsel (September 2016 to June 2020), Senior Vice President, General Counsel - US (July 2020 to July 2021), and Senior Vice President, General Counsel (July 2021 to January 2024). Most recently, Mr. Smith was promoted to Chief Legal Officer in January 2024 and is responsible for the Company's legal department, its global compliance program, and quality assurance. Mr. Smith served as Associate General Counsel at ViroPharma Incorporated from April 2008 until its acquisition by Shire plc in 2014. Prior to that, Mr. Smith served as Counsel at ConvaTec from June 2006 to April 2008. From May 2005 to June 2006, Mr. Smith was an Associate Attorney at Reed Smith LLP. Mr. Smith received his Bachelor of Science degree in Biology from Duquesne University and his Juris Doctor degree from Duquesne University School of Law.

Ms. Elizabeth McKee Anderson, M.B.A., Director since November 2018. Current Public Board Service: Director, GSK plc (LSE/NYSE: GSK); Director, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN); Director, Revolution Medicines, Inc. (Nasdaq: RVMD). Recent Public Board Service: Director until August 2022, Bavarian Nordic (CPH: BAVA). Current Private Board and Other Service: Director, Aro Biotherapeutics Inc.; Member of the Board of Trustees, The Wistar Institute. Education: Rutgers University - B.S., engineering; Loyola University Maryland - M.B.A., finance. Career Highlights: Janssen Pharmaceuticals, Inc., a Johnson & Johnson company (2003 - 2014), Worldwide Vice President, Global Strategic Marketing and Market Access, Infectious Diseases and Vaccines, Worldwide Vice President, Global Strategic Marketing and Market Access, Vaccines, Worldwide Vice President, Immunology, Global Strategic Marketing, Worldwide Vice President, BIO Strategic Marketing, Vice President, Global Biologics Strategic Marketing, Centocor, Vice President, Strategic Planning & Market Research, Centocor; Wyeth (1997 - 2002), Vice President & General Manager, Wyeth Lederle Vaccines; Rhone-Poulenc Rorer Pharmaceuticals Inc. (1993 - 1997), Senior Vice President and General Manager, North America, Centeon LLC, Vice President and General Manager, North America, Armour Pharmaceutical Company, Vice President, Worldwide Business Operations, Armour Pharmaceutical Company; American National Red Cross (1983 - 1993); Mobay Chemical Company (1979 - 1983).

Dr. Melvin Sharoky, M.D., Director since May 2001. He was Chairman from June 2009 - December 2010. Education: University of Maryland in Baltimore County - B.A., biology; University of Maryland School of Medicine - M.D.. Career Highlights: PRM Pharma, LLC (2023 - present), Principal; Par Pharmaceutical Companies, Inc. (2007 - 2012), Director until acquisition by Endo International plc (Nasdaq: ENDP); Somerset Pharmaceuticals, Inc. (1995 - 2001; 2002 - 2007), President, CEO, Consultant; Watson Pharmaceuticals, Inc. (now Allergan PLC) (1995 - 1998), President; Circa Pharmaceuticals, Inc., a wholly-owned subsidiary of Watson Pharmaceuticals, Inc. (1988 - 1998), President, CEO; Pharmakinetics Laboratories, Inc. (1986 - 1988), Vice President, Chief Medical Officer.

Dr. Clarissa Desjardins, PhD., Independent Director since November 2019. Recent Public Board Service: Director until June 2023, BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU); Director until June 2021, Xenon Pharmaceuticals (Nasdaq: XENE). Education: McGill University - B.Sc., anatomical sciences and history and philosophy of science; McGill University - Ph.D., neurology and neurosurgery; McGill University - Medical Research Council postdoctoral fellow, Douglas Hospital Research Centre. Career Highlights: Congruence Therapeutics (2021 - present), Founder and CEO; Clementia Pharmaceuticals Inc. (Nasdaq: CMTA) (2011 - 2019), acquired by Ipsen S.A. (Euronext: IPN; ADR: IPSEY) in 2019, Founder, Director, President and CEO; Centre of Excellence in Personalized Medicine (CEPMED) (2009 - 2011), President and CEO, Director; Caprion Pharmaceuticals Inc. (1998 - 2007), Co-Founder, Senior Vice President, Corporate Development, Director; Advanced Bioconcept Inc. (1992 - 1998), Co-Founder, Vice President, Business Development.

Ms. Schaeffer joined Insmed as Senior Vice President, Human Resources and Corporate Services in January 2013 and was promoted to Chief People Strategy Officer in January 2018. From October through December 2012, Ms. Schaeffer was a consultant to Insmed. Ms. Schaeffer has more than 30 years of experience in human resources, organizational development, corporate operations, and building life science organizations. From March 2005 to June 2012, Ms. Schaeffer served as Senior Vice President, Administration and Human Resources, for Amicus Therapeutics where she was responsible for the human resources, facilities, and information technology functions. Prior to Amicus, she served as Senior Director, Human Resources, for three portfolio companies of Flagship Ventures (now Flagship Pioneering), a venture capital firm, and in that capacity she managed human resources for three life sciences companies. Ms. Schaeffer also held HR leadership positions with Oak Industries, from 1997 to 2000, and EMC Corporation, from 1994 to 1996. Ms. Schaeffer received her Bachelor of Arts degree from the University of Rochester and her Master of Business Administration degree from Boston University.